Amgen to acquire Celgene’s Otezla
The transaction is expected to close by the end of 2019.
Read More
Tag: apremilast
Psoriasis patients to get NHS access to Otezla
Patients with severe plaque psoriasis living in England and Wales should now get access to Celgene’s Otezla on the NHS like their counterparts in Scotland, after cost regulators concluded that the drug is a cost-effective use of resources.
Read More
NICE backs Celgene’s Otezla for psoriatic arthritis
Celgene’s Otezla is being backed for routine use on the National Health Service in England and Wales to treat psoriatic arthritis.
Read More
NICE u-turn on Celgene’s Otezla for psoriasis
Patients with plaque psoriasis could be getting access to Celgene’s Otezla on the National Health Service in England and Wales after all, following a u-turn by cost regulators.
Read More
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
- Alzecure enters collaboration and with Lilly for Alzheimer’s project
- Survodutide trial data show targeted visceral and liver fat reductions
- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- European approval enables measles protection with CSL’s immunoglobulin Privigen
